4/24
09:51 am
idya
IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout [Yahoo! Finance]
Low
Report
IDEAYA Biosciences, Inc. (IDYA) PT Increased as Wedbush Highlights Positive OptimUM-02 Trial Readout [Yahoo! Finance]
4/21
08:13 pm
idya
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma [Ya
Low
Report
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma [Ya
4/21
10:22 am
idya
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma [Th
Low
Report
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma [Th
4/21
10:15 am
idya
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
Low
Report
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
4/14
12:18 pm
idya
IDEAYA Biosciences (IDYA) had its price target raised by The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a "neutral" rating on the stock.
Low
Report
IDEAYA Biosciences (IDYA) had its price target raised by The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a "neutral" rating on the stock.
4/14
11:10 am
idya
IDEAYA Biosciences (IDYA) had its price target raised by Wells Fargo & Company from $44.00 to $48.00. They now have an "overweight" rating on the stock.
Low
Report
IDEAYA Biosciences (IDYA) had its price target raised by Wells Fargo & Company from $44.00 to $48.00. They now have an "overweight" rating on the stock.
4/14
09:47 am
idya
IDEAYA Biosciences (IDYA) had its price target raised by Wedbush from $52.00 to $58.00. They now have an "outperform" rating on the stock.
Medium
Report
IDEAYA Biosciences (IDYA) had its price target raised by Wedbush from $52.00 to $58.00. They now have an "outperform" rating on the stock.
4/14
09:12 am
idya
IDEAYA Biosciences (IDYA) had its price target raised by Guggenheim from $50.00 to $54.00. They now have a "buy" rating on the stock.
Medium
Report
IDEAYA Biosciences (IDYA) had its price target raised by Guggenheim from $50.00 to $54.00. They now have a "buy" rating on the stock.
4/14
08:57 am
idya
IDEAYA Biosciences (IDYA) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Low
Report
IDEAYA Biosciences (IDYA) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
4/14
01:22 am
idya
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma [Yahoo! Finance]
4/13
04:08 pm
idya
IDEAYA Biosciences (IDYA) was given a new $65.00 price target by Truist Financial Corporation.
Low
Report
IDEAYA Biosciences (IDYA) was given a new $65.00 price target by Truist Financial Corporation.
4/13
06:00 am
idya
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
High
Report
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
4/10
04:05 pm
idya
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
Medium
Report
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
4/6
06:15 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer [Yahoo! Finance]
4/6
06:06 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer [TheStreet.com]
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer [TheStreet.com]
4/6
06:00 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
4/4
05:30 am
idya
Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo [Yahoo! Finance]
Low
Report
Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo [Yahoo! Finance]
4/3
07:28 pm
idya
A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses [Yahoo! Finance]
Low
Report
A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses [Yahoo! Finance]
3/31
10:20 am
idya
IDEAYA Biosciences (IDYA) had its "outperform" rating reaffirmed by Wedbush. They now have a $52.00 price target on the stock.
Low
Report
IDEAYA Biosciences (IDYA) had its "outperform" rating reaffirmed by Wedbush. They now have a $52.00 price target on the stock.
3/30
06:13 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma [Yahoo! Finance]
3/30
06:00 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
3/27
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3/22
10:14 am
idya
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial [Yahoo! Finance]
3/22
10:00 am
idya
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
Medium
Report
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
3/18
06:13 am
idya
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs [Yahoo! Finance]